Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02539459 · ClinicalTrials.gov registry record · Phase 2
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02539459 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 20 participants.
The verdict
NCT02539459, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-09-23 |
| Est. Completion | 2018-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02539459
The ClinicalTrials.gov registry entry for NCT02539459 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT02539459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02539459 about?
NCT02539459 is a clinical study titled "Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus". The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved...
What is the current status of trial NCT02539459?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-09-23. Estimated completion is 2018-08-20.
What interventions are being tested in trial NCT02539459?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT02539459?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.